Successful treatment with ceftriaxone induction and minocycline maintenance for gastrointestinal Whipple's disease.

90% of the strains were susceptible at 0.45 mg/L (range for penicillinase producing1⁄40.25 –32). Jules and Neu also confirmed that temocillin had inhibitory in vitro activity against N. gonorrhoeae at 1 mg/L regardless of the ability to produce penicillinase. The introduction of temocillin in the treatment of N. gonorrhoeae infection would be beneficial as it offers the opportunity for singledose intramuscular treatment due to a half-life of 6 h. In Denmark, the prevalence of ceftriaxone-resistant N. gonorrhoeae is low and it has not been possible to provide a ceftriaxoneresistant N. gonorrhoeae to test temocillin. The treatment options for N. gonorrhoeae are limited due to the increasing resistance to many antibiotics such as sulphonamides, penicillins, cephalosporins, tetracyclines, macrolides and fluoroquinolones. Dual antimicrobial therapy has been introduced in the USA, where ceftriaxone in combination with azithromycin or doxycycline is used. Single-dose monotherapy is still the preferred treatment in most countries. Furthermore, different new drugs are under investigation; for instance, ertapenem and solithromycin have received attention, since both drugs have good in vitro activity against gonorrhoeae isolates, including isolates that showed resistance to third-generation extended-spectrum cephalosporins. In conclusion, due to the lack of new effective antibiotics, revival of old antibiotics is needed. Temocillin will perhaps offer an extra option to cephalosporins in a limited area. Future studies should clarify the role of temocillin in the treatment of gonorrhoea in general and particularly in the treatment of ceftriaxone-resistant N. gonorrhoeae.